Article Text

PDF
▼Moxifloxacin - a new fluoroquinolone antibacterial

Abstract

▼Moxifloxacin (Avelox - Bayer plc), the latest fluoroquinolone antibacterial to be launched in the UK, is licensed for the oral treatment of adults with community-acquired pneumonia, acute exacerbation of chronic bronchitis or acute sinusitis. The company claims that the drug provides "rapid relief from chest infections". Here we review the place of moxifloxacin in treating patients with respiratory tract infections.

Statistics from Altmetric.com

  • Relevant BNF section: 5.1.12

View Full Text

Footnotes

    Request permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.